PRELIMINARY RESULTS FROM A MULTICENTER PHASE 2/3 STUDY OF NEXT-GENERATION SICKLE HEMOGLOBIN POLYMERIZATION INHIBITOR OSIVELOTOR (GBT021601) FOR THE TREATMENT OF PATIENTS WITH SICKLE CELL DISEASE
SL Sarafa, SU Abdullahib, AM Akinsetec, FA Fasolad, M Idowue, S Penningtonf, WB Ershlerg, MP Staggh, EA Lisboni, F Montealegre-Golcheri
a University of Illinois College of Medicine, Chicago, United States
b Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria
c College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria
d College of Medicine, University of Ibadan/University College Hospital, Ibadan, Nigeria
e University of Texas Health McGovern Medical School, Houston, United States
f Mississippi Center for Advanced Medicine, Madison, United States
g Inova Adult Sickle Center, Schar Cancer Institute, Fairfax, United States
h Our Lady of the Lake Cancer Institute, Baton Rouge, United States
i Pfizer Inc, New York, United States
Ver másRead
542
Timeswas read the article
188
Total PDF
354
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 7 | 17 | 6 | 23 |
| 2025 6 | 42 | 25 | 67 |
| 2025 5 | 47 | 12 | 59 |
| 2025 4 | 45 | 9 | 54 |
| 2025 3 | 52 | 10 | 62 |
| 2025 2 | 33 | 21 | 54 |
| 2025 1 | 28 | 16 | 44 |
| 2024 12 | 23 | 29 | 52 |
| 2024 11 | 35 | 37 | 72 |
| 2024 10 | 32 | 23 | 55 |
